Quantum Healthcare Ltd. (V8Y) AI Stock Analysis

• Market Cap: S$12.59M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): -3.90
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 87
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.00
• Shares Outstanding: 12,587,903,000
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.18
• Price to Book (P/B): -4.40
• Price to Sales (P/S): 1.25
• P/FCF Ratio: 14.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ―

The score is primarily held back by elevated balance-sheet risk (negative equity and meaningful debt) despite clear operational improvement (strong revenue growth, stable gross margins, narrowing losses, and positive 2024 operating/free cash flow). Limited technical and valuation data prevents confirming momentum or pricing attractiveness, keeping the overall score in the mid range.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product adoption, which can lead to improved market position and long-term profitability.

Cash Flow Improvement

Positive cash flow suggests better financial discipline and operational efficiency, enhancing the company's ability to reinvest in growth and manage debt.

Capital Restructuring

The strategic capital restructuring can strengthen the balance sheet, reduce debt burden, and improve financial flexibility, supporting long-term stability.

Negative Factors

Negative Equity

Negative equity poses a risk to financial stability and limits the company's ability to secure additional financing, impacting long-term growth potential.

High Debt Levels

High debt levels increase financial risk and interest obligations, potentially straining cash flow and limiting future investment opportunities.

Structural Loss-Making

Ongoing losses highlight challenges in achieving profitability, which can hinder long-term growth and require continued cost management efforts.

Quantum Healthcare Ltd. Business Overview & Revenue Model

Company Description

Quantum Healthcare Ltd. (V8Y) is a forward-thinking company at the forefront of the healthcare technology sector, specializing in innovative solutions that enhance patient care and streamline healthcare operations. The company focuses on developing advanced medical devices, integrated health management systems, and data analytics platforms aimed at improving clinical outcomes and operational efficiency across hospitals and clinics. With a commitment to harnessing the power of quantum computing and artificial intelligence, Quantum Healthcare aims to revolutionize how healthcare providers deliver services to patients.

How the Company Makes Money

Quantum Healthcare Ltd. generates revenue through multiple streams, primarily by selling its proprietary medical devices and software solutions to healthcare institutions, including hospitals and outpatient clinics. The company also offers subscription-based access to its health management platforms, which provide ongoing support and updates to clients. Additionally, Quantum Healthcare engages in strategic partnerships with pharmaceutical companies and research institutions, collaborating on projects that leverage its technology for drug development and clinical research, which can yield significant funding and shared revenue opportunities. Furthermore, the company may receive grants and funding from government and private organizations aimed at promoting healthcare innovation, contributing to its overall earnings.

Quantum Healthcare Ltd. Financial Statement Overview

Summary

Strong 2024 revenue growth (~+102% YoY) with stable gross margins (~44–46%) and improved profitability (net margin ~-18%). Cash flow also improved with positive operating and free cash flow in 2024. However, the balance sheet is a major risk with persistently negative equity (~-3.6M in 2024) and meaningful debt (~7.6M), keeping financial flexibility and solvency risk elevated.

Income Statement

Revenue scaled materially in 2024 (up ~102% year over year to ~12.7M), and gross margin remained solid and stable (~44–46% across 2022–2024), indicating the core product economics are reasonable. However, the company is still structurally loss-making: 2024 operating loss was ~2.1M and net loss ~2.2M (net margin ~-18%), even though profitability improved meaningfully versus 2023 (net margin ~-28%) and 2022 (near -97%). The key weakness is that operating costs are still too high relative to revenue, keeping operating and net margins negative despite top-line progress.

Balance Sheet

The balance sheet is the primary concern: stockholders’ equity is negative in every year shown (about -3.6M in 2024), which reduces financial flexibility and increases refinancing/going-concern sensitivity. Debt is sizable (~7.6M in 2024) relative to the capital base, and the negative equity makes leverage difficult to assess in a conventional way while still signaling elevated balance-sheet risk. Total assets are meaningful (~12.5M in 2024), but persistent deficits imply the company will likely need sustained profitability improvement or external capital to strengthen the capital structure.

Cash Flow

Cash generation improved notably: operating cash flow turned positive in 2024 (~1.45M) versus negative in 2023–2021, and free cash flow was also positive in 2024 (~1.10M). This suggests improved working-capital management and/or better cash discipline even while earnings remain negative. The main weakness is consistency—recent history includes multiple years of cash burn (negative operating and free cash flow in 2021–2023), so the durability of the 2024 cash improvement still needs to be proven.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.94M	12.69M	13.08M	9.37M	0.00
Gross Profit	5.87M	5.66M	5.76M	4.35M	-246.00K
EBITDA	249.00K	-318.00K	-1.45M	-7.23M	-5.03M
Net Income	-1.83M	-2.23M	-3.62M	-9.07M	-5.28M
Balance Sheet
Total Assets	11.55M	12.53M	13.03M	14.45M	916.00K
Cash, Cash Equivalents and Short-Term Investments	199.00K	386.00K	744.00K	5.07M	344.00K
Total Debt	6.86M	7.64M	6.51M	7.55M	997.00K
Total Liabilities	14.93M	15.50M	16.06M	15.35M	3.55M
Stockholders Equity	-3.96M	-3.62M	-3.87M	-1.50M	-2.59M
Cash Flow
Free Cash Flow	1.12M	1.09M	-926.00K	-2.23M	-1.30M
Operating Cash Flow	1.40M	1.45M	-628.00K	-1.30M	-1.30M
Investing Cash Flow	387.00K	-1.07M	-3.42M	-5.04M	81.00K
Financing Cash Flow	-1.88M	-733.00K	-272.00K	11.06M	240.00K

Quantum Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
V8Y	47 Neutral	S$12.59M	―	―	―	―	―

Quantum Healthcare Ltd. Corporate Events

Quantum Healthcare Converts Debt and Directors’ Fees Into Equity, Expanding Share Base

Quantum Healthcare Limited has completed a major balance sheet exercise involving the conversion of debt owed to PW Dental and the capitalisation of accrued directors’ fees into equity. On 31 December 2025, the company allotted and issued a total of 1.85 billion new shares to PW Dental and several directors, increasing its issued share capital from about 10.74 billion to 12.59 billion shares; these new shares will rank equally with existing shares except for past entitlements and are expected to begin trading on Catalist around 5 January 2026. The transaction reduces the company’s debt obligations and turns outstanding liabilities to its key creditor and directors into equity, potentially strengthening its financial position and aligning the interests of management and a significant business partner more closely with those of other shareholders.

Quantum Healthcare Ltd. Secures SGX-ST Listing Approval for Strategic Share Issuance

Quantum Healthcare Ltd. has received a listing and quotation notice from the SGX-ST for the proposed placement of new ordinary shares, conversion of debt into shares, and capitalisation of directors’ fees into shares. This development is contingent upon compliance with SGX-ST’s listing requirements and shareholder approval. The announcement signifies a strategic move to restructure the company’s capital and address outstanding financial obligations, potentially impacting its financial stability and market positioning.

Quantum Healthcare Delays Share Placement, Extends Completion Date

Quantum Healthcare Ltd. announced a delay in its proposed placement of new ordinary shares due to incomplete administrative processes and the need for additional due diligence by the placees. The company has entered into a supplemental agreement to extend the completion date for the placement to November 30, 2025, indicating a strategic move to ensure compliance and successful execution of its financial plans.